MX384716B - Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia. - Google Patents
Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.Info
- Publication number
- MX384716B MX384716B MX2016009850A MX2016009850A MX384716B MX 384716 B MX384716 B MX 384716B MX 2016009850 A MX2016009850 A MX 2016009850A MX 2016009850 A MX2016009850 A MX 2016009850A MX 384716 B MX384716 B MX 384716B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- treatment
- immunodeficiency
- microbial infections
- subject
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000000813 microbial effect Effects 0.000 title abstract 3
- 206010061598 Immunodeficiency Diseases 0.000 title abstract 2
- 208000029462 Immunodeficiency disease Diseases 0.000 title abstract 2
- 108091005804 Peptidases Proteins 0.000 title abstract 2
- 239000004365 Protease Substances 0.000 title abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000007813 immunodeficiency Effects 0.000 title abstract 2
- 239000007937 lozenge Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 241000276438 Gadus morhua Species 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000031951 Primary immunodeficiency Diseases 0.000 abstract 1
- 208000036071 Rhinorrhea Diseases 0.000 abstract 1
- 206010039101 Rhinorrhoea Diseases 0.000 abstract 1
- 102000004142 Trypsin Human genes 0.000 abstract 1
- 108090000631 Trypsin Proteins 0.000 abstract 1
- 229940112822 chewing gum Drugs 0.000 abstract 1
- 235000015218 chewing gum Nutrition 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 239000007922 nasal spray Substances 0.000 abstract 1
- 229940097496 nasal spray Drugs 0.000 abstract 1
- 239000000668 oral spray Substances 0.000 abstract 1
- 229940041678 oral spray Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201401480A GB201401480D0 (en) | 2014-01-29 | 2014-01-29 | Novel treatments |
| GBGB1405784.8A GB201405784D0 (en) | 2014-03-31 | 2014-03-31 | Novel methods, polypeptides and uses thereof |
| PCT/GB2015/050212 WO2015114343A1 (en) | 2014-01-29 | 2015-01-29 | Novel treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009850A MX2016009850A (es) | 2017-02-17 |
| MX384716B true MX384716B (es) | 2025-03-14 |
Family
ID=52630400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009850A MX384716B (es) | 2014-01-29 | 2015-01-29 | Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160339087A1 (enExample) |
| EP (2) | EP3099317B1 (enExample) |
| JP (1) | JP6718375B2 (enExample) |
| KR (1) | KR20160108560A (enExample) |
| CN (1) | CN106232810A (enExample) |
| AU (1) | AU2015212554B2 (enExample) |
| BR (1) | BR112016017478A2 (enExample) |
| DK (1) | DK3099317T3 (enExample) |
| ES (1) | ES2890555T3 (enExample) |
| MX (1) | MX384716B (enExample) |
| PL (1) | PL3099317T3 (enExample) |
| PT (1) | PT3099317T (enExample) |
| RU (1) | RU2732378C2 (enExample) |
| WO (1) | WO2015114343A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201405784D0 (en) * | 2014-03-31 | 2014-05-14 | Enzymatica Ab | Novel methods, polypeptides and uses thereof |
| EP3120866A1 (en) * | 2015-07-24 | 2017-01-25 | Zymetech ehf. | Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms |
| GB201701315D0 (en) * | 2017-01-26 | 2017-03-15 | Enzymatica Ab | Novel treatments |
| EP3863673A4 (en) * | 2018-10-11 | 2023-01-11 | Momenta Pharmaceuticals, Inc. | TREATMENT WITH HIGHLY SIALYLATED IGG COMPOSITIONS |
| CA3168643A1 (en) | 2019-02-28 | 2020-09-03 | Dandi Bioscience Inc. | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition |
| KR102368983B1 (ko) * | 2019-02-28 | 2022-03-03 | 단디바이오사이언스 주식회사 | 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물 |
| EP4344749A3 (en) * | 2020-05-13 | 2024-06-26 | ZYMIQ Technology AB | Protease formulation for treatment of microbial infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| PT1202743E (pt) | 1999-06-18 | 2005-02-28 | Jon Bragi Bjarnason | Composicoes farmaceuticas e cosmeticas compreendendo serina-proteases de bacalhau e sua utilizacao farmaceutica e cosmetica |
| WO2002006460A2 (en) * | 2000-07-13 | 2002-01-24 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| WO2011050135A1 (en) * | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| WO2012104099A1 (en) * | 2011-02-04 | 2012-08-09 | Glucometrix Ag | Process for the production of recombinant trypsin |
-
2015
- 2015-01-29 JP JP2016549436A patent/JP6718375B2/ja active Active
- 2015-01-29 EP EP15708564.8A patent/EP3099317B1/en not_active Not-in-force
- 2015-01-29 PT PT157085648T patent/PT3099317T/pt unknown
- 2015-01-29 CN CN201580017331.9A patent/CN106232810A/zh active Pending
- 2015-01-29 BR BR112016017478A patent/BR112016017478A2/pt not_active IP Right Cessation
- 2015-01-29 MX MX2016009850A patent/MX384716B/es unknown
- 2015-01-29 ES ES15708564T patent/ES2890555T3/es active Active
- 2015-01-29 PL PL15708564T patent/PL3099317T3/pl unknown
- 2015-01-29 AU AU2015212554A patent/AU2015212554B2/en not_active Ceased
- 2015-01-29 DK DK15708564.8T patent/DK3099317T3/da active
- 2015-01-29 EP EP21180866.2A patent/EP3932420A1/en not_active Withdrawn
- 2015-01-29 RU RU2016135003A patent/RU2732378C2/ru active
- 2015-01-29 US US15/115,065 patent/US20160339087A1/en not_active Abandoned
- 2015-01-29 WO PCT/GB2015/050212 patent/WO2015114343A1/en not_active Ceased
- 2015-01-29 KR KR1020167023814A patent/KR20160108560A/ko not_active Ceased
-
2019
- 2019-04-26 US US16/395,962 patent/US20190343932A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015114343A1 (en) | 2015-08-06 |
| AU2015212554B2 (en) | 2020-09-03 |
| US20190343932A1 (en) | 2019-11-14 |
| US20160339087A1 (en) | 2016-11-24 |
| KR20160108560A (ko) | 2016-09-19 |
| RU2016135003A (ru) | 2018-03-07 |
| MX2016009850A (es) | 2017-02-17 |
| RU2732378C2 (ru) | 2020-09-16 |
| PL3099317T3 (pl) | 2022-01-03 |
| EP3099317A1 (en) | 2016-12-07 |
| DK3099317T3 (en) | 2021-08-23 |
| EP3099317B1 (en) | 2021-08-04 |
| AU2015212554A1 (en) | 2016-08-18 |
| JP6718375B2 (ja) | 2020-07-08 |
| EP3932420A1 (en) | 2022-01-05 |
| PT3099317T (pt) | 2021-11-12 |
| ES2890555T3 (es) | 2022-01-20 |
| CN106232810A (zh) | 2016-12-14 |
| JP2017505624A (ja) | 2017-02-23 |
| RU2016135003A3 (enExample) | 2019-02-14 |
| BR112016017478A2 (pt) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384716B (es) | Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia. | |
| DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2016002971A1 (es) | Combinación. | |
| MX2020007049A (es) | Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus. | |
| CO2017008148A2 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| MX2017014204A (es) | Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2. | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| MX2019009860A (es) | Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea. | |
| MX377510B (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
| MX2021000542A (es) | Apirasas solubilizadas, metodos y usos. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CO2020014399A2 (es) | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX387201B (es) | Composiciones para el tratamiento contra infecciones. | |
| MX390488B (es) | Composicion farmaceutica de clorhidrato de amantadina-loratadina-paracetamol para integrar una capsula, para el tratamiento de refriados entre otras alopatias. | |
| AR104200A1 (es) | Carboximetilcisteina para tratamiento tópico de estrías | |
| AR122764A2 (es) | Formulación de un polipéptido del factor viii, kit farmacéutico, método | |
| AR104549A1 (es) | Formulaciones de tripeptidil peptidasa 1 (tpp1) y métodos de tratamiento de una lipofuscinosis ceroide neuronal (cln2) | |
| UA126148U (uk) | Спосіб лікування періімплантного мукозиту | |
| EA201991866A1 (ru) | Комбинированная терапия |